Deinove, Avril sign deal to assess commercial potential of 20 new bacterial strains

May 23, 2015 |

In France, Deinove and Avril announced that they would screen a 6,000-bacteria bank of Deinococci and other genera to identify 20 strains capable of producing useful molecules in terms of animal nutrition and health, and AVRIL Group would characterize the molecules produced and to perform application tests. The goal of this new stage is to confirm each molecule’s potential and to optimize production conditions.

This 3-year collaboration agreement, called COLOR2B, signed in August 2014 between DEINOVE and SOFIPROTEOL (renamed AVRIL), is part of the DEINOCHEM program. Co-financed by the two partners, COLOR2B is an R&D project, which aims at developing a production process for natural feed additives. This includes selecting the best-performing bacteria strains from DEINOVE’s strain bank, testing the compounds produced, qualifying their benefits for animal nutrition and health as well as developing the production process at pilot-scale.

“We have already demonstrated that our bacteria are very well suited to industrial production. Today, the highly positive start to this collaboration validates the biodiversity of our bacterial heritage,” said Emmanuel Petiot, CEO of DEINOVE. “As we move forward in analyzing our strain bank, we discover new potential applications. It is very promising for our future development with the AVRIL Group and other partners in various fields such as nutrition, or cosmetics.”

More on the story.

Print Friendly, PDF & Email

Tags: ,

Category: Research

Thank you for visting the Digest.